146 related articles for article (PubMed ID: 12747939)
1. Opioids and the apoptotic pathway in human cancer cells.
Zagon IS; McLaughlin PJ
Neuropeptides; 2003 Apr; 37(2):79-88. PubMed ID: 12747939
[TBL] [Abstract][Full Text] [Related]
2. Opioids and migration, chemotaxis, invasion, and adhesion of human cancer cells.
Zagon IS; Rahn KA; McLaughlin PJ
Neuropeptides; 2007 Dec; 41(6):441-52. PubMed ID: 17910895
[TBL] [Abstract][Full Text] [Related]
3. Opioids and differentiation in human cancer cells.
Zagon IS; McLaughlin PJ
Neuropeptides; 2005 Oct; 39(5):495-505. PubMed ID: 16169076
[TBL] [Abstract][Full Text] [Related]
4. Opioid growth factor (OGF) inhibits anchorage-independent growth in human cancer cells.
Zagon IS; McLaughlin PJ
Int J Oncol; 2004 Jun; 24(6):1443-8. PubMed ID: 15138586
[TBL] [Abstract][Full Text] [Related]
5. Opioid growth factor tonically inhibits human colon cancer cell proliferation in tissue culture.
Zagon IS; Hytrek SD; McLaughlin PJ
Am J Physiol; 1996 Sep; 271(3 Pt 2):R511-8. PubMed ID: 8853370
[TBL] [Abstract][Full Text] [Related]
6. Opioid growth factor regulates the cell cycle of human neoplasias.
Zagon IS; Roesener CD; Verderame MF; Ohlsson-Wilhelm BM; Levin RJ; McLaughlin PJ
Int J Oncol; 2000 Nov; 17(5):1053-61. PubMed ID: 11029512
[TBL] [Abstract][Full Text] [Related]
7. Low-dose naltrexone targets the opioid growth factor-opioid growth factor receptor pathway to inhibit cell proliferation: mechanistic evidence from a tissue culture model.
Donahue RN; McLaughlin PJ; Zagon IS
Exp Biol Med (Maywood); 2011 Sep; 236(9):1036-50. PubMed ID: 21807817
[TBL] [Abstract][Full Text] [Related]
8. Ultra-low doses of naltrexone or etorphine increase morphine's antinociceptive potency and attenuate tolerance/dependence in mice.
Shen KF; Crain SM
Brain Res; 1997 May; 757(2):176-90. PubMed ID: 9200746
[TBL] [Abstract][Full Text] [Related]
9. Potency differences for D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 as an antagonist of peptide and alkaloid micro-agonists in an antinociception assay.
Sterious SN; Walker EA
J Pharmacol Exp Ther; 2003 Jan; 304(1):301-9. PubMed ID: 12490605
[TBL] [Abstract][Full Text] [Related]
10. Opioid antagonist modulation of murine neuroblastoma: a profile of cell proliferation and opioid peptides and receptors.
Zagon IS; McLaughlin PJ
Brain Res; 1989 Feb; 480(1-2):16-28. PubMed ID: 2540873
[TBL] [Abstract][Full Text] [Related]
11. Etorphine inhibits cell growth and induces apoptosis in SK-N-SH cells: involvement of pertussis toxin-sensitive G proteins.
Yin DL; Ren XH; Zheng ZL; Pu L; Jiang LZ; Ma L; Pei G
Neurosci Res; 1997 Oct; 29(2):121-7. PubMed ID: 9359460
[TBL] [Abstract][Full Text] [Related]
12. Opioid antagonist-induced receptor upregulation: effects of concurrent agonist administration.
Yoburn BC; Duttaroy A; Shah S; Davis T
Brain Res Bull; 1994; 33(2):237-40. PubMed ID: 8275346
[TBL] [Abstract][Full Text] [Related]
13. The opioid growth factor, [Met5]-enkephalin, and the zeta opioid receptor are present in human and mouse skin and tonically act to inhibit DNA synthesis in the epidermis.
Zagon IS; Wu Y; McLaughlin PJ
J Invest Dermatol; 1996 Mar; 106(3):490-7. PubMed ID: 8648182
[TBL] [Abstract][Full Text] [Related]
14. Antagonists at excitatory opioid receptors on sensory neurons in culture increase potency and specificity of opiate analgesics and attenuate development of tolerance/dependence.
Shen KF; Crain SM
Brain Res; 1994 Feb; 636(2):286-97. PubMed ID: 8012813
[TBL] [Abstract][Full Text] [Related]
15. Homeostasis of ocular surface epithelium in the rat is regulated by opioid growth factor.
Zagon IS; Sassani JW; Kane ER; McLaughlin PJ
Brain Res; 1997 Jun; 759(1):92-102. PubMed ID: 9219867
[TBL] [Abstract][Full Text] [Related]
16. Different types of opioid receptors mediating analgesia induced by morphine, DAMGO, DPDPE, DADLE and beta-endorphin in mice.
Suh HH; Tseng LF
Naunyn Schmiedebergs Arch Pharmacol; 1990 Jul; 342(1):67-71. PubMed ID: 1976234
[TBL] [Abstract][Full Text] [Related]
17. Chronic exposure to mu-opioid agonists produces constitutive activation of mu-opioid receptors in direct proportion to the efficacy of the agonist used for pretreatment.
Liu JG; Prather PL
Mol Pharmacol; 2001 Jul; 60(1):53-62. PubMed ID: 11408600
[TBL] [Abstract][Full Text] [Related]
18. The opioid growth factor, [Met5]-enkephalin, inhibits DNA synthesis during recornification of mouse tail skin.
Wilson RP; McLaughlin PJ; Lang CM; Zagon IS
Cell Prolif; 2000 Apr; 33(2):63-73. PubMed ID: 10845251
[TBL] [Abstract][Full Text] [Related]
19. Potentiation of the excitatory action of NMDA in ventrolateral periaqueductal gray by the mu-opioid receptor agonist, DAMGO.
Kow LM; Commons KG; Ogawa S; Pfaff DW
Brain Res; 2002 May; 935(1-2):87-102. PubMed ID: 12062477
[TBL] [Abstract][Full Text] [Related]
20. Opioid agonist and antagonist treatment differentially regulates immunoreactive mu-opioid receptors and dynamin-2 in vivo.
Yoburn BC; Purohit V; Patel K; Zhang Q
Eur J Pharmacol; 2004 Sep; 498(1-3):87-96. PubMed ID: 15363980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
